Professor, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
W. T. and Louise Jarrett Moran Distinguished Chair in Pediatric Oncology, Department of Pediatrics - Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Ph.D. Washington State University, Pullman, WA, Cell Wall Biology, 1993
Shanxi State University, Shanxi, China, BS, Biological Science, 1985
Post doctorate, Molecular Immunology, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993-1997
Summer Xia, M.S.
Research Laboratory Coordinator
M.S. Washington State University, 1993
Summer is providing central support to laboratory members for molecular assays, molecularcloning, gene structure design, which are routinely needed for understandingbiological questions and developing novel immune therapy. Her other role is to coordinate laboratory operations.
Jiemiao Hu, Ph.D.
Ph. D. University of Texas Graduate School of Biomedical Sciences, 2012
Jiemiao’s research focuses on delivering T cells, tumor infiltrating lymphocytes (TILs) and chimeric antigenreceptor (CAR) T cells into solid tumors. She discovered that the combination of certain chemotherapy and immunotherapy facilitates the penetration of T cells into human xenograft and PDX solid tumors. Further, such therapeutic strategy greatly enhances the effector T cell functions, and therefore boosts the immune surveillance in tumor microenvironment, resulting in tumor remission and extended survival. This novel approach to delivering T cells may broaden the application of T cell therapy to a wider range of solid tumors.
Hobbies: Zumba, hiking, music and playing with dogs
Zhiliang Jia, PhD.
PhD. Cancer Biology, The University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, 2010
Zhiliang is interested in developing and testing immune therapy of pediatric cancer on humanized mouse model. Mouse model with human immune cell engraftment represent ground-breaking platform to evaluate treatments of cancer. Replacement of mouse gene with human gene can target the gene and subsequently the functional protein molecule. With mouse that reconstituted human immune system, interaction of human immune cells with tumor cells could be determined. Experimental results produced from the system will be more relevant and promising.
Sheng Zhang, M.D., M.S., Ph.D
Senior Research Scientist
Sheng’s research focuses on the new drugs and immunotherapies of small molecular inhibitors, therapeutic antibodies, ADC, chimeric antigen-receptor cells such as CAR-T, CAR-NK, and CAR-NKT, tumor infiltrating lymphocytes, tumor cell vaccine, etc. He collaborates with different investigators in the biomedical discovery. His studies will apply different novel approaches and strategies in the future treatments of human diseases.